CDKN2A and adenocarcinoma: Diagnostic pathways are moving beyond a binary “HPV-associated/independent” label toward integrated algorithms combining HPV DNA/RNA testing, p16 immunohistochemistry, targeted next-generation sequencing, and, where available, methylation profiling, to correctly classify HPV-independent adenocarcinomas and to surface actionable targets at diagnosis and recurrence [138,139].